LUMOS PHARMA, INC.: basic earnings per share

What this measure means

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

Exact concept: us-gaap:EarningsPerShareBasic. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.

Coverage of this history

Selected reporting periods run from 2012-01-01 to 2023-12-31. The SEC response was captured on 2026-09-21.

This selected history ends more than two years before capture. Do not treat its final value as a current balance or current annual result. More recent filings may use another accounting tag; inspect the filings before drawing conclusions about the company.

Selected filing history

Related financial histories

• LUMOS PHARMA, INC.: total assets
• LUMOS PHARMA, INC.: total liabilities
• LUMOS PHARMA, INC.: stockholders equity
• LUMOS PHARMA, INC.: cash and cash equivalents
• LUMOS PHARMA, INC.: net income or loss
• LUMOS PHARMA, INC.: operating cash flow
• LUMOS PHARMA, INC.: capital expenditure payments
• LUMOS PHARMA, INC.: revenue
• LUMOS PHARMA, INC.: contract revenue excluding tax
• LUMOS PHARMA, INC.: financing cash flow
• LUMOS PHARMA, INC.: investing cash flow
• LUMOS PHARMA, INC.: retained earnings or deficit
• LUMOS PHARMA, INC.: basic weighted-average shares
• LUMOS PHARMA, INC.: diluted weighted-average shares
• LUMOS PHARMA, INC.: diluted earnings per share
• LUMOS PHARMA, INC.: income tax expense or benefit
• LUMOS PHARMA, INC.: net property, plant and equipment
• LUMOS PHARMA, INC.: share-based compensation expense
• LUMOS PHARMA, INC.: operating income or loss
• LUMOS PHARMA, INC.: current assets
• LUMOS PHARMA, INC.: interest expense
• LUMOS PHARMA, INC.: current liabilities
• LUMOS PHARMA, INC.: current accounts payable
• LUMOS PHARMA, INC.: common-stock repurchase payments
• LUMOS PHARMA, INC.: operating expenses
• LUMOS PHARMA, INC.: research and development expense
• LUMOS PHARMA, INC.: common shares outstanding
• LUMOS PHARMA, INC.: cash including restricted cash
• LUMOS PHARMA, INC.: additional paid-in capital
• LUMOS PHARMA, INC.: accumulated other comprehensive income or loss
• LUMOS PHARMA, INC.: total equity including noncontrolling interests
• LUMOS PHARMA, INC.: operating lease right-of-use asset
• LUMOS PHARMA, INC.: operating lease liability
• LUMOS PHARMA, INC.: gross property, plant and equipment
• LUMOS PHARMA, INC.: accumulated depreciation on property, plant and equipment
• LUMOS PHARMA, INC.: accrued current liabilities
• LUMOS PHARMA, INC.: prepaid expenses and other current assets
• LUMOS PHARMA, INC.: net deferred tax assets
• LUMOS PHARMA, INC.: pre-tax income or loss from continuing operations
• LUMOS PHARMA, INC.: profit or loss including noncontrolling interests
• LUMOS PHARMA, INC.: comprehensive income or loss
• LUMOS PHARMA, INC.: net income available to common stockholders
• LUMOS PHARMA, INC.: general and administrative expense
• LUMOS PHARMA, INC.: depreciation, depletion and amortization
• LUMOS PHARMA, INC.: other nonoperating income or expense
• LUMOS PHARMA, INC.: nonoperating income or expense
• LUMOS PHARMA, INC.: current income tax expense or benefit
• LUMOS PHARMA, INC.: deferred income tax expense or benefit
• LUMOS PHARMA, INC.: interest paid, net
• LUMOS PHARMA, INC.: proceeds from issuing common stock
• LUMOS PHARMA, INC.: change in accounts payable

Inspect the source

Entity

LUMOS PHARMA, INC. / CIK 0001126234

Captured

2026-09-21T17:18:00.364Z

SEC response SHA-256

85afc03c2955198a89cc2dd3621a736c3fff6534667ea93c5cbc2f4d4a91f030

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

• Get an API key and run your first validation
• Connect the MCP server to your coding assistant
• Inspect the ALPHAC engine on GitHub
• Read the MCP server source and integration examples

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001126234.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))